期刊文献+

Statins for primary cardiovascular prevention in the elderly

Statins for primary cardiovascular prevention in the elderly
下载PDF
导出
摘要 The elderly population is increasing worldwide, with subjects 〉 65 years of age constituting the fastest-growing age group. Furthermore, the elderly face the greatest risk and burden of cardiovascular disease mortality and morbidity. Although elderly patients, particularly those older 〉 75, have not been well represented in randomized clinical trials evaluating lipid-lowering therapy, the available evidence supporting the use of statin therapy in primary prevention in older individuals is derived mainly from subgroup analyses and post-hoc data. On the other hand, elderly patients often have multiple co-morbidities that require a high number of concurrent medications; this may increase the risk for drug-drug interactions, thereby reducing the potential benefits of statin therapy. The aim of this review was to present the relevant literature regarding statin use in the elderly for theft primary cardiovascular disease, with the associated risks and benefits of treatment.
出处 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2015年第4期431-438,共8页 老年心脏病学杂志(英文版)
关键词 Cardiovascular disease DYSLIPIDAEMIA ELDERLY Primary prevention STATINS 心血管疾病 他汀类药物 中老年人 预防 药物相互作用 药物治疗 年龄组 世界范围
  • 相关文献

参考文献82

  • 1Go AS, Mozaffarian D, Roger VL, et al; Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
  • 2Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
  • 3Stone NJ, Robinson JG, Lichtenstein Att, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Asso- ciation Task Force on Practice Guidelines. JAm Coll Cardiol 2014; 63: 2889-2934.
  • 4Strandberg TE, Kolehrnainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clini- cal review. JAMA 2014; 312:1136-1144.
  • 5Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-1870.
  • 6Lavie CJ. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug com- binations. Am J Geriatr Cardiol 2004; 13 (Suppl 1): S29-S33.
  • 7Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc 2009; 101: 705-710.
  • 8Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol 2010; 4: 483-490.
  • 9Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults. A scien- tific statement from the American Heart Association. Circula- tion 2013; 128: 2422-2446.
  • 10Zannad F, Dallongeville J, Macfadyen RJ, et al. Prevention of cardiovascular disease guided by total risk estimations-chal- lenges and opportunities for practical implementation: high- lights of a CardioVascular Clinical Trialists (CVCT) Work- shop of the ESC Working Group on CardioVascular Pharma- cology and Drag Therapy. Eur J Prey Cardiol 2012; 19: 1454-1464.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部